[Neuroinflammation: Dr Jekyll or Mr Hyde?]. / La neuro-inflammation - Dr Jekyll ou Mr Hyde ?

Sheltered in a bony cage, populated by cells with little regenerative potential, the central nervous system (CNS) could likely not withstand classic inflammation without risking major sequelae. As a consequence, it had to develop an original way to provide surveillance, defence and reparation, which relies on both the complex architecture of the periphery-nervous parenchyma exchange zones, and the tightly regulated collaboration between all the cell populations that reside in or pass through the CNS. Despite its tight regulation, neuroinflammation is sometimes the cause of irreversible loss but it is also where the solution stands. The specific immune crosstalk that takes place in the CNS needs to be decoded in order to identify the best therapeutic strategies aimed at helping the CNS to restore homeostasis in problematic situations, such as in the case of neurodegenerative disorders. This review deals with this double-edged sword nature of neuroinflammation.

The intrasplenic circulation of three formulations of the same protein antigen.

This paper presents a kinetic study of the intrasplenic circulation of three formulations of the protein antigen conalbumin including the soluble form and two liposomal formulations, one encapsulated in the internal aqueous milieu and one surface-linked to the liposomal vehicle. These formulations differ not only in their physical status but also in their immunostimulating properties and were chosen in an attempt to correlate the movements of antigen in lymphoid tissues with the immune response elicited. The presence of conalbumin was followed over a period of 21 days using, as a detection system, an antibody that we developed and which allows for the visualization of antigenic peptides such as those presented at the surface of antigen-presenting cells (APC). The results demonstrate that the amount of antigen accessing to the spleen, its time of residency and the pathway it follows are all profoundly influenced by the form under which it penetrates the immune system. The results also indicate that the marked initial preferences of an antigen for either B cells, marginal zone macrophages (MZM) or metallophilic macrophages (MM) are of fundamental importance in determining the fate of this antigen in the spleen. It is concluded that the exact formulation of an antigen is as crucial to the regulation of the immune response as is the nature of this antigen. It is further concluded that liposomes can be used efficiently to modify the formulation of an antigen and can contribute as such to the induction of specific immune functions by driving the antigen towards some privileged immune cell populations.

Effect of liposomal antigens on the priming and activation of the immune system by dendritic cells.

Dendritic cells (DCs) are recognized as the sole professional antigen-presenting cells capable of priming naive T cells of the helper and cytotoxic phenotypes. This property is presently exploited with success in vaccinal strategies against pathogens or tumor cells that otherwise escape immune recognition, but the repeated infusions of ex vivo expanded and sensitized DCs are usually required to achieve protection. In this paper, we demonstrate that liposomal antigens can efficiently relay and propagate the action of DCs, inducing a strong long-term response against their associated antigen. Their effect is mainly achieved by improving the ex vivo loading of DCs and by efficiently channeling the activation stimulus into the induction of effector function. This is demonstrated by the sustained immunoglobulin production as well as by the sustained lymphoproliferation and the increased cytokine secretion that can be achieved upon restimulation of DC-primed immune cells with limited amount of liposomal antigenic material. Being well-tolerated and easily prepared, liposomal antigens could therefore be expected to significantly contribute to the efficiency and to a more general utilization of the highly promising but rather cumbersome DC-based immunotherapies.